Dr. Mary J. Janatpour from Dynavax Technologies | Oncotarget (VIDEO)
Caption
<p>Low-dose cyclophosphamide decreases Tregs. Additional impacted biological activities have been described, such as:</p> <ul> <li>increased interferon production,</li> <li>induction of immunogenic cell death,</li> <li>increases in effector T cells, and</li> <li>increases in functional NK cells,</li> </ul> <p>...likely to be complementary to SD-101 activity by virtue of modulation of the TME. By administering <a target="_blank" href="http://investors.dynavax.com/news-releases/news-release-details/dynavax-presents-phase-2-data-sd-101-combination-keytrudar">SD-101</a> locally, rather than systemically, the researchers demonstrate that localized SD-101 injection combined with systemically administered low-dose <a target="_blank" href="http://chemocare.com/chemotherapy/drug-info/cyclophosphamide.aspx">cyclophosphamide</a> confers an anti-tumor response at non-injected sites.</p>
Credit
www.oncotarget.com
Usage Restrictions
ccby
License
Licensed content